Cargando…

Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences

Bone remodelling is related to coordinated phases of bone resorption and bone apposition allowing the maintenance of bone integrity, the phosphocalcic homoeostasis all along the life and consequently the bone adaptation to mechanical constraints or/and to endocrine fluctuations. Unfortunately, bone...

Descripción completa

Detalles Bibliográficos
Autor principal:	Heymann, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723324/ https://www.ncbi.nlm.nih.gov/pubmed/26909248 http://dx.doi.org/10.1016/j.jbo.2012.03.001

Ejemplares similares

Clinical development of anti-RANKL therapy
por: Schwarz, Edward M, et al.
Publicado: (2007)

RANK–RANKL signalling in cancer
por: Renema, Nathalie, et al.
Publicado: (2016)

From discovery of RANKL to clinical application of anti-human RANKL antibody
por: Yasuda, Hisataka, et al.
Publicado: (2012)

Tumours—Basic Principles and Clinical Aspects
por: Bush, H.
Publicado: (1979)

Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma
por: Muñoz-Garcia, Javier, et al.
Publicado: (2022)

Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL
por: Picarda, Gaëlle, et al.
Publicado: (2013)

Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine
por: Tellez-Gabriel, Marta, et al.
Publicado: (2018)

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
por: Infante, Marco, et al.
Publicado: (2019)

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
por: Kawanami, Daiji, et al.
Publicado: (2016)

Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate
por: Brennan, Meadhbh Á, et al.
Publicado: (2014)

The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL
por: Simatou, Aristofania, et al.
Publicado: (2020)

RANKL biology: bone metabolism, the immune system, and beyond
por: Ono, Takehito, et al.
Publicado: (2020)

Recent Clinical Treatment and Basic Research on the Alveolar Bone
por: Tsuchida, Sachio, et al.
Publicado: (2023)

Bone Turnover Markers: Basic Biology to Clinical Applications
por: Schini, Marian, et al.
Publicado: (2022)

Polytrauma: update on basic science and clinical evidence
por: Nauth, Aaron, et al.
Publicado: (2021)

RANKL/RANK: from bone loss to the prevention of breast cancer
por: Sigl, Verena, et al.
Publicado: (2016)

RANKL is a therapeutic target of bone destruction in rheumatoid arthritis
por: Tanaka, Sakae
Publicado: (2019)

Uremic Sarcopenia: Clinical Evidence and Basic Experimental Approach
por: Nishi, Hiroshi, et al.
Publicado: (2020)

Curcumin and Colorectal Cancer: From Basic to Clinical Evidences
por: Pricci, Maria, et al.
Publicado: (2020)

Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis
por: Tellez-Gabriel, Marta, et al.
Publicado: (2016)

Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males
por: Findlay, David, et al.
Publicado: (2008)

Distinct patterns of RANKL/osteoprotegerin system modulation through anti-tumour necrosis factor and corticosteroid therapy in rheumatoid arthritis synovium
por: Catrina, AI, et al.
Publicado: (2005)

The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases
por: Navet, Benjamin, et al.
Publicado: (2018)

Recent developments in palifermin basic, pre-clinical and clinical research
por: Rubin, Jeffrey S
Publicado: (2013)

Maternal RANKL Reduces the Osteopetrotic Phenotype of Null Mutant Mouse Pups
por: Navet, Benjamin, et al.
Publicado: (2018)

RANK, RANKL and osteoprotegerin in bone biology and disease
por: Wright, H. L., et al.
Publicado: (2009)

Soy Isoflavones and Bone Health: Focus on the RANKL/RANK/OPG Pathway
por: Hooshiar, Saeedeh Hosseini, et al.
Publicado: (2022)

RANKL Expression in Periodontal Disease: Where Does RANKL Come from?
por: Chen, Bin, et al.
Publicado: (2014)

Regulation of neurite growth by tumour necrosis superfamily member RANKL
por: Gutierrez, Humberto, et al.
Publicado: (2013)

Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor
por: Coleman, RE
Publicado: (2009)

Photodynamic Therapy: Basic Principles and Clinical Applications
por: Moore, J.V.
Publicado: (1993)

Origins of Alterations to Rankl Null Mutant Mouse Dental Root Development
por: Gama, Andrea, et al.
Publicado: (2020)

Pasteurization of bone for tumour eradication prior to reimplantation – An in vitro & pre-clinical efficacy study
por: Kode, Jyoti, et al.
Publicado: (2014)

Targeting RANKL in metastasis
por: Dougall, William C, et al.
Publicado: (2014)

Primary Retention of Molars and RANKL Signaling Alteration during Craniofacial Growth
por: Gama, Andrea, et al.
Publicado: (2020)

Regulation of RANKL signaling in arthritic bone destruction
por: Takayanagi, H
Publicado: (2003)

Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence
por: Mas, Marta, et al.
Publicado: (2022)

Role of the Gut–Liver Axis in the Pathobiology of Cholangiopathies: Basic and Clinical Evidence
por: Bragazzi, Maria Consiglia, et al.
Publicado: (2023)

Pre-, pro- and synbiotics in cancer prevention and treatment—a review of basic and clinical research
por: Scott, Alasdair J, et al.
Publicado: (2018)

The induced membrane technique for bone defects: Basic science, clinical evidence, and technical tips
por: Hoit, Graeme, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v59fgkihmd1scclgq032il4dd1